IN2014DN11272A - - Google Patents

Info

Publication number
IN2014DN11272A
IN2014DN11272A IN11272DEN2014A IN2014DN11272A IN 2014DN11272 A IN2014DN11272 A IN 2014DN11272A IN 11272DEN2014 A IN11272DEN2014 A IN 11272DEN2014A IN 2014DN11272 A IN2014DN11272 A IN 2014DN11272A
Authority
IN
India
Prior art keywords
recombinant
protein
mammalian cells
present
fge
Prior art date
Application number
Inventor
Chun Zhang
Ferenc Boldog
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of IN2014DN11272A publication Critical patent/IN2014DN11272A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/99—Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides among other things methods and compositions for large scale production of recombinant I2S protein using suspension culture of mammalian cells in serum free medium. In particular the present invention uses mammalian cells co express a recombinant I2S protein and a formylglycine generating enzyme (FGE).
IN11272DEN2014 2012-06-29 2013-06-28 IN2014DN11272A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666712P 2012-06-29 2012-06-29
PCT/US2013/048601 WO2014005036A1 (en) 2012-06-29 2013-06-28 Method of producing recombinant iduronate-2-sulfatase

Publications (1)

Publication Number Publication Date
IN2014DN11272A true IN2014DN11272A (en) 2015-10-09

Family

ID=49778402

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11272DEN2014 IN2014DN11272A (en) 2012-06-29 2013-06-28

Country Status (21)

Country Link
US (1) US20140004097A1 (en)
EP (1) EP2867367A4 (en)
JP (1) JP2015523074A (en)
KR (1) KR20150037908A (en)
CN (1) CN104583414A (en)
AU (1) AU2013282417A1 (en)
BR (1) BR112014032544A2 (en)
CA (1) CA2877492A1 (en)
CL (1) CL2014003569A1 (en)
CO (1) CO7240395A2 (en)
CR (1) CR20140587A (en)
DO (1) DOP2014000297A (en)
EA (1) EA201492185A1 (en)
HK (2) HK1209458A1 (en)
IL (1) IL236324A0 (en)
IN (1) IN2014DN11272A (en)
MX (1) MX2015000188A (en)
PE (1) PE20150603A1 (en)
PH (1) PH12014502870A1 (en)
SG (1) SG11201408755TA (en)
WO (1) WO2014005036A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101380740B1 (en) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 Purification of iduronate-2-sulfatase
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US9932565B2 (en) 2012-07-31 2018-04-03 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
ES2774549T3 (en) 2013-03-13 2020-07-21 Bioasis Technologies Inc Fragments of P97 and uses thereof
DK3107562T3 (en) * 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-IDS FUSION PROTEIN
CA2973343C (en) 2015-02-05 2023-08-08 R.P. Scherer Technologies, Llc Activated formylglycine-generating enzymes and methods of producing and using the same
CN108290059A (en) * 2015-10-07 2018-07-17 乔尔·胡伊赞加 Biological approach is reseted to defend and repair the degeneration from mankind's aging
AU2016354009B2 (en) 2015-11-09 2021-05-20 R.P. Scherer Technologies, Llc Anti-CD22 antibody-maytansine conjugates and methods of use thereof
CA3032099A1 (en) * 2016-07-25 2018-02-01 Repligen Corporation Alternating tangential flow rapid harvesting
CR20200129A (en) 2017-10-02 2020-08-22 Denali Therapeutics Inc Fusion proteins comprising enzyme replacement therapy enzymes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008934A1 (en) 1996-08-30 1998-03-05 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
EP1171615B1 (en) * 1999-04-26 2006-12-13 Genentech, Inc. Cell culture process for glycoproteins
US6890736B1 (en) * 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
AU2004210936C1 (en) * 2003-02-11 2010-12-02 Takeda Pharmaceutical Company Limited Diagnosis and treatment of Multiple Sulfatase Deficiency and other using a Formylglycine Generating Enzyme (FGE)
US20050019914A1 (en) * 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
PL1885753T3 (en) * 2005-06-03 2011-12-30 Ares Trading Sa Production of recombinant Il-18 binding protein
CA2630782C (en) * 2005-12-08 2015-02-03 Amgen Inc. Improved host cells and culture methods
WO2009091994A2 (en) * 2008-01-18 2009-07-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
DK2485761T3 (en) * 2009-10-09 2019-05-06 Armagen Inc Methods and compositions for increasing iduronate-2-sulfatase activity in the CNS
WO2011109600A1 (en) * 2010-03-05 2011-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation pattern of a polypeptide
US8545837B2 (en) 2010-06-25 2013-10-01 Shire Human Genetic Therapies, Inc. Methods and compositions for CNS delivery of iduronate-2-sulfatase
KR101158673B1 (en) * 2011-06-24 2012-07-03 주식회사 지씨바이오 Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase

Also Published As

Publication number Publication date
HK1209790A1 (en) 2016-04-08
HK1209458A1 (en) 2016-04-01
EA201492185A1 (en) 2015-10-30
CL2014003569A1 (en) 2015-04-17
SG11201408755TA (en) 2015-02-27
CA2877492A1 (en) 2014-01-03
PH12014502870A1 (en) 2015-02-23
MX2015000188A (en) 2015-04-08
EP2867367A1 (en) 2015-05-06
BR112014032544A2 (en) 2017-08-01
EP2867367A4 (en) 2016-02-24
AU2013282417A1 (en) 2015-01-29
US20140004097A1 (en) 2014-01-02
KR20150037908A (en) 2015-04-08
WO2014005036A1 (en) 2014-01-03
CR20140587A (en) 2015-04-06
DOP2014000297A (en) 2015-04-15
JP2015523074A (en) 2015-08-13
IL236324A0 (en) 2015-02-26
PE20150603A1 (en) 2015-05-27
CN104583414A (en) 2015-04-29
CO7240395A2 (en) 2015-04-17

Similar Documents

Publication Publication Date Title
IN2014DN11272A (en)
MX2012001742A (en) Production of proteins in glutamine-free cell culture media.
MX2013003681A (en) Engineered nucleic acids and methods of use thereof.
MX2021008143A (en) Methods for harvesting mammalian cell cultures.
PH12016500011A1 (en) Cells for producing recombinant iduronate-2-sulfatase
MX2016004564A (en) Metabolically optimized cell culture.
WO2012118799A3 (en) Cell culture system
MX344970B (en) Cell culture medium for adamts protein expression.
MX2019003427A (en) Cell culture compositions and methods for polypeptide production.
MX2013005853A (en) Fusion enzymes having n-acetylglucosaminyltransferase activity.
MX2015012875A (en) Cell culture compositions with antioxidants and methods for polypeptide production.
MY180183A (en) Methods and compositions for preventing norleucine misincorporation into proteins
IN2014CN02963A (en)
EA201170025A1 (en) METHODS OF INCREASING THE VIABILITY AND PRODUCTION OF CULTURE OF CELLS
MX2010005079A (en) Methods of measuring cell viability without using control cells.
AU2018276376A1 (en) Cell culture methods
CA2830600C (en) Compositions and methods for enhancing the pluripotency of stem cells
MX2015010887A (en) Formulations and methods for increased recombinant protein production.
WO2015117033A3 (en) Methods of increasing protein production in mammalian cells